Last edition
News about Global Pharma
Eugia Pharma Specialities Ltd Gets USFDA Final Approval for Posaconazole Injection
The product is expected to be launched in December 2023. The approved product has an estimated market size of USD 25.4 million for the twelve months ending October 2023, according to IQVIA.
Global Pharma | 28/12/2023 | By Manvi | 1431
Sanjivani Paranteral Raises Funds through Issuance of Warrants & Preferential Allotment
The company also approved preferential allotment of 16,86,000 equity shares at Rs 135.10 per share, amounting to Rs 22.77 crores to non-promoter investors.
Global Pharma | 28/12/2023 | By Manvi | 1047
The product will be manufactured at Lupin’s Pithampur facility in India. Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Global Pharma | 28/12/2023 | By Manvi | 832
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site
PharmaBlock Sciences (Nanjing), Inc. has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and above) at its Zhejiang manufacturing site.
Global Pharma | 28/12/2023 | By Manvi | 693
Under this strategic collaboration, Menarini India has obtained exclusive rights to market and distribute the dermo-cosmetic brands, EAU THERMALE AVÈNE and DUCRAY in India.
Global Pharma | 27/12/2023 | By Manvi | 1386
AstraZeneca to Buy China-Based Gracell Biotechnologies in USD 1.2 Billion Deal
The cash deal aimed at bolstering AstraZeneca's portfolio values US listed Gracell at $2 per ordinary share or USD 10 per ADS of Gracell, plus a non-tradable contingent value right of USD 0.30 per ordinary share, if certain regulatory milestones are met.
Global Pharma | 27/12/2023 | By Manvi | 725
Four Workers Hospitalised After Inhaling Toxic Gas at Pharma Chemical Factory
Four workers were hospitalised after they inhaled toxic gas leaking from a pipe at a pharmaceutical chemical company in Vadodara city of Gujarat, police said.
Global Pharma | 27/12/2023 | By Manvi | 577
USFDA Inspects Aurobindo Pharma's New Jersey-Based Facility,Issues 10 Observations
The United States Food and Drug Administration (USFDA) issued 10 observations after conducting a pre-approval inspection at a facility linked to wholly-owned arm of Aurobindo Pharma in New Jersey
Global Pharma | 26/12/2023 | By Manvi | 1112
Zydus Lifesciences Receives 6 Observations from USFDA for API Site at Changodar
The inspection closed with 6 observations. There were no Data Integrity related observations. There are no repeat observations from the previous inspection.
Global Pharma | 26/12/2023 | By Manvi | 655
AstraZeneca and Ionis' Wainua Granted First-Ever Regulatory Approval in US
AstraZeneca and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. Wainua is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.
Global Pharma | 26/12/2023 | By Manvi | 708
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy